The Solopath Balloon Expandable Transfemoral Introducer
Onset Medical
FDA Clearance Information
The SoloPath Balloon Expandable Transfemoral Introducer was cleared by the FDA via the 510(k) pathway on August 2, 2010. It is manufactured by Onset Medical and classified as a Class 2 device.
What It Is
FDA-Cleared Indications
- Vascular access for introducing diagnostic or therapeutic catheters and other intravascular devices.
- Transfemoral access in endovascular procedures requiring an introducer sheath.
- Use in procedures requiring large-bore arterial access, according to the device labeling and sizing specifications.
Clinical Applications
- Obtaining femoral arterial access for catheter-based cardiovascular procedures.
- Providing a conduit for large catheters or devices during transfemoral endovascular treatment.
- Supporting transfemoral access during structural-heart procedures such as transcatheter aortic valve implantation when compatible with the labeled device configuration.
Evidence Summary
Reported Outcomes
Safety Profile
Evidence Limitations
Practical Considerations
- The appropriate sheath diameter and length depend on the planned device, access-vessel anatomy and the manufacturer's compatibility specifications.
- The device is inserted through transfemoral vascular access under fluoroscopic or other appropriate imaging guidance, with balloon expansion performed according to the instructions for use.
- Small, calcified, tortuous or severely diseased access vessels may increase the risk of dissection, perforation, bleeding or vessel occlusion; preprocedure imaging and careful patient selection are important.
- Use only with compatible guidewires, catheters and intravascular devices listed in the current instructions for use.
- MRI safety and conditional-use information should be confirmed in the current manufacturer labeling; this record does not establish that the device is MR Safe or MR Conditional.
Frequently Asked Questions
What are the clinical indications for SoloPath Balloon Expandable Transfemoral Introducer?
The device is indicated for use in procedures requiring large-bore vascular access, such as TAVI, particularly in patients with peripheral artery disease.
What outcomes have been reported in clinical studies?
Studies report improved access-site availability and reduced vascular complications in patients undergoing TAVI.
What complications have been reported?
Safety data indicate minimal adverse events, with vascular complications being the primary concern, though not directly attributed to the device.